JP2019014676A - カプセル剤 - Google Patents
カプセル剤 Download PDFInfo
- Publication number
- JP2019014676A JP2019014676A JP2017132762A JP2017132762A JP2019014676A JP 2019014676 A JP2019014676 A JP 2019014676A JP 2017132762 A JP2017132762 A JP 2017132762A JP 2017132762 A JP2017132762 A JP 2017132762A JP 2019014676 A JP2019014676 A JP 2019014676A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- eldecalcitol
- polyethylene glycol
- tocopherol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 229950005556 eldecalcitol Drugs 0.000 claims abstract description 31
- FZEXGDDBXLBRTD-SJSKTVLPSA-N eldecalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@H](O)[C@H](OCCCO)[C@@H](O)C1=C FZEXGDDBXLBRTD-SJSKTVLPSA-N 0.000 claims abstract description 31
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 26
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000011732 tocopherol Substances 0.000 claims abstract description 15
- 229930003799 tocopherol Natural products 0.000 claims abstract description 15
- 229960001295 tocopherol Drugs 0.000 claims abstract description 15
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 15
- 235000010388 propyl gallate Nutrition 0.000 claims abstract description 14
- 239000000473 propyl gallate Substances 0.000 claims abstract description 14
- 229940075579 propyl gallate Drugs 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 34
- 238000011049 filling Methods 0.000 claims description 19
- 239000007901 soft capsule Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229960000984 tocofersolan Drugs 0.000 description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960003511 macrogol Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- 235000005282 vitamin D3 Nutrition 0.000 description 5
- 239000011647 vitamin D3 Substances 0.000 description 5
- 229940021056 vitamin d3 Drugs 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- -1 medium-chain fatty acid triglycerides Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017132762A JP2019014676A (ja) | 2017-07-06 | 2017-07-06 | カプセル剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017132762A JP2019014676A (ja) | 2017-07-06 | 2017-07-06 | カプセル剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019014676A true JP2019014676A (ja) | 2019-01-31 |
| JP2019014676A5 JP2019014676A5 (enrdf_load_html_response) | 2020-08-13 |
Family
ID=65358355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132762A Pending JP2019014676A (ja) | 2017-07-06 | 2017-07-06 | カプセル剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2019014676A (enrdf_load_html_response) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110898016A (zh) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | 一种用于预防和治疗小儿佝偻病的艾地骨化醇滴剂的制备方法 |
| CN110934846A (zh) * | 2019-12-11 | 2020-03-31 | 正大制药（青岛）有限公司 | 艾地骨化醇胶囊及其制备方法 |
| JP2021024844A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール含有医薬組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0632740A (ja) * | 1992-05-20 | 1994-02-08 | F Hoffmann La Roche Ag | 医薬製剤 |
| WO2005074943A1 (ja) * | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | Ｅｄ−７１製剤 |
| CN101564398A (zh) * | 2009-05-19 | 2009-10-28 | 邵爱霞 | 一种多维生素软胶囊及其制备方法 |
-
2017
- 2017-07-06 JP JP2017132762A patent/JP2019014676A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0632740A (ja) * | 1992-05-20 | 1994-02-08 | F Hoffmann La Roche Ag | 医薬製剤 |
| WO2005074943A1 (ja) * | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | Ｅｄ−７１製剤 |
| CN101564398A (zh) * | 2009-05-19 | 2009-10-28 | 邵爱霞 | 一种多维生素软胶囊及其制备方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021024844A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール含有医薬組成物 |
| CN110898016A (zh) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | 一种用于预防和治疗小儿佝偻病的艾地骨化醇滴剂的制备方法 |
| CN110934846A (zh) * | 2019-12-11 | 2020-03-31 | 正大制药（青岛）有限公司 | 艾地骨化醇胶囊及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7282832B2 (ja) | 安定化調整放出ビタミンｄ製剤及びその投与方法 | |
| EP0487575B1 (en) | Pharmaceutical formulations | |
| US20080160077A1 (en) | Soft Gel Formulations | |
| JP2019014676A (ja) | カプセル剤 | |
| JP6742487B1 (ja) | エルデカルシトール含有医薬組成物 | |
| JP2012180337A (ja) | 自己乳化製剤 | |
| JP6589725B2 (ja) | 液体眼科用組成物、眼科用製品及び白濁抑制方法 | |
| JP2015168630A (ja) | カプセル充填組成物 | |
| JP2019206518A (ja) | 油脂含有組成物及び経口製剤 | |
| JP2012180287A (ja) | カンデサルタンシレキセチルのカプセル充填用組成物 | |
| JPWO2016195057A1 (ja) | ソフトカプセル剤 | |
| JPH03128322A (ja) | ポリプレニル系化合物を含有する医薬組成物およびその製造方法 | |
| JP6628927B1 (ja) | エルデカルシトール軟カプセル剤 | |
| KR102050070B1 (ko) | 산화안정성이 있는 유지조성물 및 이를 포함하는 연질캡슐제제 | |
| JP6271696B2 (ja) | 薬剤組成物、及びこれを密封してなる軟カプセル剤 | |
| WO2019151353A1 (ja) | 注射用製剤の製造方法 | |
| JPWO2019088274A1 (ja) | 医薬組成物、医薬組成物の安定化方法、及び医薬組成物の保存安定性を評価する方法 | |
| JP7022973B2 (ja) | ソフトカプセル充填用組成物およびソフトカプセル剤 | |
| JP2024060510A (ja) | 油性組成物及びそれを含むカプセル製剤 | |
| JPS6270317A (ja) | 活性型ビタミンｄ↓３類含有製剤 | |
| JP4677289B2 (ja) | 油性外用基剤 | |
| JPWO2019230971A1 (ja) | ジブチルヒドロキシトルエンの含量低下が抑制された眼科用液剤 | |
| WO2014010008A1 (ja) | カンデサルタンシレキセチルのカプセル充填用組成物 | |
| NZ711924B2 (en) | Stabilized modified release vitamin d formulation and method of administering same | |
| JP2014058491A (ja) | 医薬品組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200702 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200702 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210727 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220201 |